Abstract
In elderly people the respiratory function is affected by anatomical and physiological modifications caused by aging. Elderly COPD patients are characterized by a complexity due to an increasing prevalence of comorbidities related to the age that suggest peculiar care in prescribing the therapy in those patients, also considering other disabilities that are not related with respiratory disorders as physical and mental limitations. Nowadays a therapy that allows modifying the long-term decline in lung function of patients suffering from COPD does not yet exist and, therefore, the treatment of this disease is mainly focused on the administration of bronchodilators and the use of inhaled glucocorticoids. As for younger subjects, also in elderly patients the main classes of bronchodilators used in the treatment of COPD include β2-agonists, anticholinergics and methylxanthines. The inflammatory response suppression represents another mechanistic approach for treating COPD in the elderly, although the use of inhaled corticosteroids is limited to specific indications. Indeed, nowadays there is a strong medical need for novel treatments of COPD in the elderly. These are mainly represented by agents that reduce the spillover of inflammatory mediators from the lung and by compounds that inhibit the chronic systemic inflammatory syndrome. The therapeutic approach of COPD in elderly patients remains a topic of increasing interest, however the development of novel compounds for preventing the COPD progression in the elderly, other than bronchodilators and corticosteroids, remains a challenge.
Keywords: Elderly, aging, COPD, bronchodilator agents, anti-inflammatory agents, combined therapy, adverse effects.
Current Pharmaceutical Design
Title:New Treatments for COPD in the Elderly
Volume: 20 Issue: 38
Author(s): Maria Gabriella Matera, Luigino Calzetta, Paola Rogliani, Alfredo Cesario and Mario Cazzola
Affiliation:
Keywords: Elderly, aging, COPD, bronchodilator agents, anti-inflammatory agents, combined therapy, adverse effects.
Abstract: In elderly people the respiratory function is affected by anatomical and physiological modifications caused by aging. Elderly COPD patients are characterized by a complexity due to an increasing prevalence of comorbidities related to the age that suggest peculiar care in prescribing the therapy in those patients, also considering other disabilities that are not related with respiratory disorders as physical and mental limitations. Nowadays a therapy that allows modifying the long-term decline in lung function of patients suffering from COPD does not yet exist and, therefore, the treatment of this disease is mainly focused on the administration of bronchodilators and the use of inhaled glucocorticoids. As for younger subjects, also in elderly patients the main classes of bronchodilators used in the treatment of COPD include β2-agonists, anticholinergics and methylxanthines. The inflammatory response suppression represents another mechanistic approach for treating COPD in the elderly, although the use of inhaled corticosteroids is limited to specific indications. Indeed, nowadays there is a strong medical need for novel treatments of COPD in the elderly. These are mainly represented by agents that reduce the spillover of inflammatory mediators from the lung and by compounds that inhibit the chronic systemic inflammatory syndrome. The therapeutic approach of COPD in elderly patients remains a topic of increasing interest, however the development of novel compounds for preventing the COPD progression in the elderly, other than bronchodilators and corticosteroids, remains a challenge.
Export Options
About this article
Cite this article as:
Matera Gabriella Maria, Calzetta Luigino, Rogliani Paola, Cesario Alfredo and Cazzola Mario, New Treatments for COPD in the Elderly, Current Pharmaceutical Design 2014; 20 (38) . https://dx.doi.org/10.2174/1381612820666140314154331
DOI https://dx.doi.org/10.2174/1381612820666140314154331 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
microRNAs as New Targets of Dietary Polyphenols
Current Pharmaceutical Biotechnology Duration of Dual Antiplatelet Therapy After Coronary Stenting
Current Pharmaceutical Design Poor Response to Antiplatelet Drugs. An Important Issue in Drug-Eluting Stents.
Current Clinical Pharmacology Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges
Current Pharmaceutical Design Parvovirus B19 (B19V) Infection and Pregnancy
Current Pediatric Reviews Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery Myocardial Revascularization Strategies in Diabetic Patients with Multi-Vessel Disease: CABG vs DES-Based PCI
Current Pharmaceutical Design Recent Developments in the Treatment of Alcoholic Chronic Pancreatitis
Current Drug Abuse Reviews AMPK As A Target in Rare Diseases
Current Drug Targets Sirtuins Family- Recent Development as a Drug Target for Aging, Metabolism, and Age Related Diseases
Current Drug Targets Obstructive Sleep Apnea and Type 2 Diabetes: Dual Interaction
Current Respiratory Medicine Reviews Placebos Used in Clinical Trials for Chinese Herbal Medicine
Recent Patents on Inflammation & Allergy Drug Discovery Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Current Stem Cell Research & Therapy What Changes we may Expect in 2010 Hypertension Diagnosis and Management: Insights from the European Update Document
Current Vascular Pharmacology Insights into Pharmacological Potential of Apigenin through Various Pathways on a Nanoplatform in Multitude of Diseases
Current Pharmaceutical Design Update on the Pharmacological Treatment of Alzheimers Disease
Current Neuropharmacology Medical and Dental Implications of Down Syndrome: A Review Part 1: General and Craniofacial Characteristic
Applied Clinical Research, Clinical Trials and Regulatory Affairs Editorial [Hot Topic: Analgesic Drug Discovery: Promising Future (Guest Editor: Anindya Bhattacharya)]
Current Pharmaceutical Biotechnology From Antidepressant Drugs to Beta-Mimetics: Preclinical Insights on Potential New Treatments for Neuropathic Pain
Recent Patents on CNS Drug Discovery (Discontinued) Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?
Current Pharmaceutical Design